A Universal Method for the Determination of Amlodipine in Industrial and Extemporaneous Pharmaceutical Preparations

Authors

DOI:

https://doi.org/10.24959/ophcj.26.346798

Keywords:

amlodipine besylate, pharmaceutical market analysis, market availability of medicines, UV-spectrophotometry, standardization, quality, off-label, extemporaneous preparations

Abstract

A universal UV spectrophotometric method for determining amlodipine besylate in industrially manufactured and extemporaneously prepared medicinal products in the form of tablets, powders, and oral solutions has been developed and validated. The methodological concept is based on the use of a single analytical model applicable to various dosage forms and dissolution media without modifying the analytical conditions. Spectral studies confirmed the presence of two absorption maxima at (238 ± 2) nm and (365 ± 2) nm, which corresponded to different chromophoric systems of the molecule and could be used to identify the compound; the wavelength of 365 nm was selected as the analytical wavelength, providing improved selectivity for the quantitative determination of the active pharmaceutical ingredient. The method was validated in accordance with pharmacopoeial requirements and ICH guidelines. The procedure is characterized by precision, accuracy, specificity, and linearity in the range of 0.04–0.06 μg mL-1 (80–120% of the nominal concentration) (r > 0.9981) in all solvents proposed. The limits of detection (LOD) and quantification (LOQ) calculated were 0.59% and 0.92% for medicinal products in tablet and powder dosage forms, and 0.84% and 1.09% for the oral solution, respectively. The uncertainty of the method, including contributions from the sample preparation and the final analytical operation, was within acceptable limits for spectrophotometric assay procedures. The method proved to be applicable to industrial tablets, as well as extemporaneous powders and oral solutions, without interference from excipients in different dissolution media. Due to the minimal solvent consumption and the absence of requirements for chromatographic equipment, the approach proposed is an environmentally friendly, affordable and acceptable alternative from the point of view of regulatory requirements for the routine quality control of amlodipine medicinal products, particularly in small-scale production.

Supporting Agency

  • The authors received no specific funding for this work.

Downloads

Download data is not yet available.

References

  1. Hypertension. World Health Organization (WHO), https://www.who.int/news-room/fact-sheets/detail/hypertension/?gad_source=1&gclid=CjwKCAjwrvyxBhAbEiwAEg_KggM2vAWActF3ldiwk_7moMRXYNPSu03MfdYQUo_oug2yupCVqPirWxoCE2EQAvD_BwE (accessed 2025-10-02).
  2. Wang, J. G.; Palmer, B. F.; Vogel Anderson, K.; Sever, P. Amlodipine in the Current Management of Hypertension. J. Clin. Hypertens. 2023, 25 (9), 801–807. https://doi.org/10.1111/jch.14709.
    | |
  3. Gonchar, A.; Sholoiko, N.; Kosyachenko, K.; Komarida, O. Research on the Consumption of Two-Component Fixed Combinations of Medicines for the Treatment of Arterial Hypertension in Ukraine (2020–2023). Sci. Rise: Pharm. Sci. 2025, 4 (56), 4–19. https://doi.org/10.15587/2519-4852.2025.336898.
    |
  4. Derzhavnyi reiestr likarskykh zasobiv Ukrainy [State Register of Medicinal Products of Ukraine, in Ukrainian]. https://www.drlz.com.ua (accessed 2025-11-08).
  5. Han, X.; Hong, X.; Li, X.; Wang, Y.; Wang, Z.; Zheng, A. Optimization of Personalized Amlodipine Dosing Strategies for Children Based on Pharmacokinetic Data and PBPK Modeling. Children 2021, 8 (11), 950. https://doi.org/10.3390/children8110950.
    | |
  6. van der Vossen, A. C.; Cransberg, K.; de Winter, B. C. M.; Schreuder, M. F.; van Rooij-Kouwenhoven, R. W. G.; Vulto, A. G.; Hanff, L. M. Use of Amlodipine Oral Solution for the Treatment of Hypertension in Children. Int. J. Clin. Pharm. 2020, 42 (3), 848–852. https://doi.org/10.1007/s11096-020-01000-9.
    | |
  7. European Pharmacopoeia, 11th Ed.; European Directorate for the Quality of Medicines & HealthCare: Strasbourg, France
  8. British Pharmacopoeia (2024 ed.); Medicines and Healthcare products Regulatory Agency (MHRA): London, UK
  9. Derzhavna farmakopeia Ukrainy, 2 vydannia, tom 1 [The State Pharmacopoeia of Ukraine, 2nd Ed., vol. 1, in Ukrainian]; State Enterprise “Ukrainian Scientific Pharmacopoeial Center for Quality of Medicines”: Kharkiv, 2015.
  10. Nakaz MOZ Ukrainy No. 812 vid 17.10.2012 r. [Order of the Ministry of Health of Ukraine No. 812 “On Approval of the Rules for the Manufacture and Quality Control of Medicinal Products in Pharmacies”, in Ukrainian]. https://zakon.rada.gov.ua/laws/show/z1846-12#Text.
  11. United States Pharmacopeial Convention. United States Pharmacopeia and National Formulary (USP 46–NF 41); United States Pharmacopeial Convention: Rockville, MD, 2023.
  12. Derzhavna farmakopeia Ukrainy, 2 vydannia, tom 2, dopovnennia 7 [The State Pharmacopoeia of Ukraine, 2nd Ed., vol. 2, suppl. 7 in Ukrainian]; State Enterprise “Ukrainian Scientific Pharmacopoeial Center for Quality of Medicines”: Kharkiv, 2015.
  13. Jeelani, S.; Kouznetsova, N. A New Stability-Indicating HPLC–UV Method for Determination of Amlodipine Besylate and Its Impurities. Heliyon 2023, 9 (9), e19993. https://doi.org/10.1016/j.heliyon.2023.e19993.
    | |
  14. Sharkawi, M. M. Z.; Mohamed, N. R.; El-Saadi, M. T.; Amin, N. H. Validated Green Chromatographic Methods for Determination of Amlodipine and Celecoxib. Bioanalysis 2021, 13 (12), 969–983. https://doi.org/10.4155/bio-2021-0040.
    | |
  15. Abu Reid, I. O.; Farid, H. M.; Eltayeb, S. O. Simple Spectrophotometric Methods for Determination of Amlodipine and Atorvastatin. Future J. Pharm. Sci. 2021, 7, 232. https://doi.org/10.1186/s43094-021-00377-2.
  16. Faisal, M. S.; Sawan, M. S.; Naz, Z.; Bin Khalil, N. A. Quantitative Analysis of Amlodipine Tablets Using UV Spectrophotometry. Acad. J. Sci. Technol. 2024, 3 (1), 158–162. https://doi.org/10.64095/ajst.v3i1.59.
  17. Birajdar, K.; Kalshetti, M. S. Development and Validation of a UV Spectrophotometric Method for Estimation of Amlodipine Besylate. Int. J. Sci. Res. Sci. Technol. 2024, 11, 456–460. https://doi.org/10.32628/IJSRST24113119.
  18. Alkhalil, R.; Attal, A.; Sakur, A. Spectrophotometric Determination of Amlodipine Besylate Using Amido Black. Res. J. Pharm. Technol. 2019, 12 (7), 3389–3392.
  19. Sulyma, M.; Vasyuk, S.; Zhuk, Y.; Kaminskyy, D.; Chupashko, O.; Ogurtsov, V. New Spectrophotometric Method of Amlodipine Besylate Determination and Its Validation. Chem. Chem. Technol. 2018, 12 (4), 429–433.
  20. Meher, A. K.; Zarouri, A. Green Analytical Chemistry—Recent Innovations. Analytica 2025, 6 (1), 10. https://doi.org/10.3390/analytica6010010.
    |
  21. Pena-Pereira, F.; Wojnowski, W.; Tobiszewski, M. AGREE—Analytical GREEnness Metric Approach and Software. Anal. Chem. 2020, 92 (14), 10076–10082. https://doi.org/10.1021/acs.analchem.0c01887.
    | |

Downloads

Published

2026-04-23

How to Cite

(1)
Bevz, O. V.; Kryvanych, O. V.; Bevz, N. Y.; Georgiyants, V. A. A Universal Method for the Determination of Amlodipine in Industrial and Extemporaneous Pharmaceutical Preparations. J. Org. Pharm. Chem. 2026, 24, 3-12.

Issue

Vol. 24 No. 1 (2026): Issue in Progress

Section

Original Researches

License

Copyright (c) 2026 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors publishing their works in the Journal of Organic and Pharmaceutical Chemistry agree with the following terms:

1. Authors retain copyright and grant the journal the right of the first publication of the work under Creative Commons Attribution License allowing everyone to distribute and re-use the published material if proper citation of the original publication is given.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book) providing proper citation of the original publication.

3. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on authors’ personal websites) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).